Collegium Pharmaceutical (COLL) Debt to Equity (2014 - 2026)

Collegium Pharmaceutical's Debt to Equity history runs 13 years deep, the most recent figure standing at $1.81 for Q1 2026.

• In Q1 2026, Debt to Equity fell 29.45% year-over-year to $1.81; the TTM figure through Mar 2026 stood at $1.81 (down 29.45% YoY), while the FY2025 annual figure was $1.89, down 29.59% from the prior year.
• Debt to Equity was $1.81 for Q1 2026 at Collegium Pharmaceutical, down from $1.89 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $3.2 in Q1 2022 to a low of $1.46 in Q2 2024.
• Historically, Debt to Equity has averaged $2.41 across 5 years, with a median of $2.51 in 2023.
• The sharpest annual moves came in 2022 and 2024: Debt to Equity jumped 508.57% in 2022, then plunged 45.67% in 2024.
• A 5-year view of Debt to Equity shows it stood at $2.87 in 2022, then decreased by 27.9% to $2.07 in 2023, then increased by 29.73% to $2.69 in 2024, then dropped by 29.59% to $1.89 in 2025, then fell by 4.58% to $1.81 in 2026.
• The last three Debt to Equity figures came in at $1.81 (Q1 2026), $1.89 (Q4 2025), and $1.84 (Q3 2025), per Business Quant data.